A Phase I Clinical Study of Anti-CEA CAR-T Therapy in the Treatment of CEA-positive Advanced Malignant Solid Tumors
Latest Information Update: 18 Mar 2025
At a glance
- Drugs Anti CEA CAR T cell therapy-Chongqing Precision Biotech (Primary) ; Anti CEA CAR T cell therapy-Chongqing Precision Biotech (Primary) ; Cyclophosphamide; Fludarabine
- Indications Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
Most Recent Events
- 14 Mar 2025 Planned number of patients changed from 72 to 50.
- 20 Feb 2025 New trial record